Perspectives on cardiac allograft vasculopathy
Related Experiment Video
Updated: Aug 10, 2026
Orthotopic Aortic Transplantation: A Rat Model to Study the Development of Chronic Vasculopathy
Published on: December 4, 2010
1Section of Heart Failure and Cardiac Transplant Medicine, Kaufman Center for Heart Failure, Department of Cardiology (Desk F-25), The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA. youngj@ccf.org
Insights
Allograft arteriopathy, a form of chronic rejection after heart transplant, causes graft failure. Future treatments may focus on controlling the immune response to prevent this atherosclerosis.
Area of Science:
- Cardiology
- Transplantation Immunology
- Vascular Biology
Background:
- Allograft arteriopathy, or chronic rejection, is a major cause of late cardiac graft failure and death post-heart transplant.
- This condition involves both immune and nonimmune factors, potentially linked to donor-transmitted atherosclerosis or initial endothelial health.
- Current treatments for allograft arteriopathy are limited and yield suboptimal outcomes.
Purpose of the Study:
- To summarize the current understanding of allograft arteriopathy, its contributing factors, and potential therapeutic strategies.
- To highlight the need for improved management of this critical post-transplant complication.
Main Methods:
- Review of experimental models and clinical data, including intravascular ultrasound studies.
- Analysis of existing literature on immune and nonimmune factors in allograft arteriopathy.
- Evaluation of current and emerging treatment modalities.
Main Results:
- Allograft arteriopathy is a multifactorial process involving immune and nonimmune pathways.
- Intravascular ultrasound provides valuable insights into the progression of this condition.
- Several agents, including diltiazem, pravastatin, ganciclovir, novel immunosuppressants, and photopheresis, show potential benefit.
Conclusions:
- Effective control of the allograft immunologic response is crucial for attenuating the development of allograft arteriopathy.
- Further research is needed to develop more effective treatments for chronic rejection after heart transplantation.
Abstract:
Allograft arteriopathy, the slowly progressive, diffuse, atherosclerosis noted often after heart transplant, and also called chronic rejection, is the most common cause of late cardiac graft failure and patient death. The process is multifactorial, rooted in both immune and nonimmune factors that can be coupled to passenger atherosclerosis moved with the donor heart, as well as initially nondiseased endothelium. Great insight has emerged from experimental models and intravascular ultrasound study of patients, but treatments are still crude and produce less than optimal results. Nonetheless, it has been demonstrated that diltiazem, pravastatin, ganciclovir, newer immunosuppressive agents, and photophoresis may be helpful. In the future, better control of the allograft immunologic response will likely be the key to attenuating development of this form of atherosclerosis.
